Literature DB >> 34529221

The role of transforming growth factor beta in thyroid autoimmunity: current knowledge and future perspectives.

Efstratios Kardalas1, Evangelos Sakkas1,2, Marek Ruchala3, Djuro Macut4, George Mastorakos5.   

Abstract

The complex mechanisms, which are related to the pathophysiology and the development of autoimmune thyroid diseases, involve transforming growth factor beta (TGF-β) and its interplay with the immune system. The aim of this review is to examine the role of TGF-β regarding thyroid autoimmunity and explore the potent role of this molecule either as a diagnostic or prognostic marker or a therapeutic target regarding autoimmune thyroid diseases. TGF-β is clearly a master regulator of the immune response, exerting either inhibitory or facilitatory effects on cells of the immune system. Thus, this molecule is involved in the pathogenesis and development of autoimmune thyroid diseases. Recent research has revealed the involvement of TGF-β in the pathophysiology of autoimmune thyroid diseases. The role of TGF-β in the development of autoimmune thyroid diseases varies, depending on its concentrations, the type of the activated TGF-β signalling pathway, the genetic predisposition of the patient and the pathophysiologic stage of the disease. TGF-β could emerge as a useful diagnostic or prognostic marker for the evolution of thyroid autoimmunity. Promising perspectives for the effective therapeutic use of TGF-β regarding thyroid autoimmunity exist. The main treatment approaches incorporate either enhancement of the immunosuppressive role of TGF-β or inhibition of its facilitatory role in the autoimmune thyroid diseases. Further research towards deeper understanding of TGF-β physiology and clinical application of its possible therapeutic role regarding thyroid autoimmunity is needed.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Autoimmune thyroid diseases; Immune system; TGF-β; Thyroid gland; Thyroiditis

Mesh:

Substances:

Year:  2021        PMID: 34529221     DOI: 10.1007/s11154-021-09685-7

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  83 in total

Review 1.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

Review 2.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 3.  Graves' Disease.

Authors:  Terry J Smith; Laszlo Hegedüs
Journal:  N Engl J Med       Date:  2016-10-20       Impact factor: 91.245

Review 4.  Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy.

Authors:  Alessandro Antonelli; Poupak Fallahi; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Ilaria Ruffilli; Armando Patrizio; Debora Gonnella; Claudia Giusti; Camilla Virili; Marco Centanni; Yehuda Shoenfeld; Silvia Martina Ferrari
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2020-02-04       Impact factor: 4.690

Review 5.  Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy.

Authors:  Francesca Ragusa; Poupak Fallahi; Giusy Elia; Debora Gonnella; Sabrina Rosaria Paparo; Claudia Giusti; Leonid P Churilov; Silvia Martina Ferrari; Alessandro Antonelli
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2019-11-26       Impact factor: 4.690

6.  Downregulated miR-187 contributes to the keratinocytes hyperproliferation in psoriasis.

Authors:  Lipeng Tang; Songmin He; Ying Zhu; Bing Feng; Zuqing Su; Bo Liu; Fangfang Xu; Xieqi Wang; Hongying Liu; Chutian Li; Jie Zhao; Xirun Zheng; Caiyun Li; Chaoyue Sun; Chuanjian Lu; Guangjuan Zheng
Journal:  J Cell Physiol       Date:  2018-09-14       Impact factor: 6.384

7.  Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis.

Authors:  N Mitsiades; V Poulaki; V Kotoula; G Mastorakos; S Tseleni-Balafouta; D A Koutras; M Tsokos
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

Review 8.  Thyroid autoimmunity in the current iodine environment.

Authors:  Labrini Papanastasiou; Ioannis-Anastasios Vatalas; Demetrios A Koutras; George Mastorakos
Journal:  Thyroid       Date:  2007-08       Impact factor: 6.568

Review 9.  Immunogenetics of autoimmune thyroid diseases: A comprehensive review.

Authors:  Hanna J Lee; Cheuk Wun Li; Sara Salehi Hammerstad; Mihaela Stefan; Yaron Tomer
Journal:  J Autoimmun       Date:  2015-07-30       Impact factor: 7.094

Review 10.  Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.

Authors:  Natacha Turck; Simone Eperon; Maria De Los Angeles Gracia; Aurélie Obéric; Mehrad Hamédani
Journal:  Dis Markers       Date:  2018-03-15       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.